No Data
No Data
Jia Biyou (688089.SH) received a warning letter from the Hubei Securities Regulatory Bureau
Jia Biyou (688089.SH) announced that on May 15, 2024, the company received the “Decision of the Hubei Securities Regulatory Bureau on Issuing Warning Letter Measures against Jiabiyou Biotechnology (Wuhan) Co., Ltd., Yi Dewei, Yi Huarong, and Wang Huabiao” ([2024] No. 24) (“Warning Letter”) issued by the Hubei Regulatory Bureau of the China Securities Regulatory Commission.
The synthetic biology concept opened high and went low. Jiabiyou fell more than 5%, Tebao Biotech and Shengda Biotech fell by more than 4%, and Boen Group and Hanyu Pharmaceutical collectively fell.
The synthetic biology concept opened high and went low. Jiabiyou fell more than 5%, Tebao Biotech and Shengda Biotech fell by more than 4%, and Boen Group and Hanyu Pharmaceutical collectively fell.
Express News | Jia Biyou: The company's daily business situation is normal and there have been no major changes recently
The food processing sector fluctuated and boosted. Jiabiyou surged 13%, Qiaqia Foods rose more than 6%, and Bowling Bao, Sweet Foods, Jinzai Foods, and Hairong Technology followed suit.
The food processing sector fluctuated and boosted. Jiabiyou surged 13%, Qiaqia Foods rose more than 6%, and Bowling Bao, Sweet Foods, Jinzai Foods, and Hairong Technology followed suit.
The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.
The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.
Jia Biyou (688089): Gross margin improved year-on-year in Q1 beyond expectations
Guide to this report: The 24Q1 company's performance exceeded expectations, mainly due to a significant recovery in revenue from overseas customers and a recovery in gross margin. Subsequent major overseas customers and new HMO product expansion are expected to help medium- to long-term growth. Investment Highlights: Investment Suggestions to Consider
No Data